Targeting CD47 as a Novel Immunotherapy for Breast Cancer
Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor‐targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety an...
Main Authors: | Can Chen, Runlu Wang, Xi Chen, Yulong Hou, Jingting Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.924740/full |
Similar Items
-
Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01) -
Deciphering the role of CD47 in cancer immunotherapy
by: Yu'e Liu, et al.
Published: (2024-09-01) -
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
The landscape overview of CD47-based immunotherapy for hematological malignancies
by: Hua Yang, et al.
Published: (2023-02-01) -
Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers
by: Milad Zandi, et al.
Published: (2023-07-01)